AlphaMadera's AlphaVal page computes Stepan Company's fair value using a multi-method blend (DCF, comparable-multiples, and Graham-style intrinsic value), then compares it to the current market price to flag SCL as undervalued, fairly valued, or overvalued.

What is Stepan Company's fair value?

Fair value for SCL is a model output combining discounted cash flow projections, peer-group multiples, and a Graham number floor. The live AlphaVal page shows the blended fair value alongside each method's individual estimate.

How does AlphaMadera value SCL?

AlphaVal uses three primary techniques: a five-year discounted-cash-flow projection with terminal multiple, peer-group multiple analysis (P/E, EV/EBITDA, P/S), and Graham's defensive-investor intrinsic-value formula. Inputs come from SCL's most recent reported fundamentals.

SCL - Stepan Company

Price: -- -- | CONSENSUS: Buy DETAILS | PRICE TARGET: $75.00 DETAILS

AlphaVal

Deterministic, archetype-aware fair value

Stable Earnings Power 65% confidence

Primary model: P/Adj-EPS × Normalized Multiple

Valuation Signal Fair Value Mild

Trading 13.4% below fair value

Current Price $52.07

Bear Case $48.10 7.6% downside ($48.10 - $52.07) / $52.07 = -7.6% $4.01 × 12x P/E

Fair Value $60.12 15.5% upside ($60.12 - $52.07) / $52.07 = 15.5% $4.01 × 15x P/E

Bull Case $72.14 38.6% upside ($72.14 - $52.07) / $52.07 = 38.6% $4.01 × 18x P/E

Adjust Assumptions

P/E Multiple

15.0x

Adjusted EPS

4.01$

Key Value Driver

Normalized P/E multiple (15x base case)

Implied Market Multiple 13.0x

Plain-Language Summary

Applying a 15x P/E to adjusted EPS of $4.01, the base-case value is $60.12 per share. DDM cross-check: $37.75.

Warnings

⚠ The company's reported profits differ from official accounting profits by 96%. Check what costs are being left out of the adjusted number.

ℹ Dividend-based valuation: $37.75 (below our primary estimate by 37%). Large gaps may signal the dividend doesn't reflect full earning power.

Key Risks

Growth DCF inappropriate — terminal value assumptions dominate
EV/EBITDA misleading for regulated businesses where capex is mandated
Regulatory risk is a fat tail not visible in normal multiples